Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MP Materials (MP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

MP MaterialsTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

MP Materials vs State Street SPDR S&P Biotech ETF — how do they compare? MP Materials trades at $54.55 (market cap $9.86B), while State Street SPDR S&P Biotech ETF trades at $160. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals.

MPXBI
Market Cap
$9.86B
Sector
IndustrialsBroad Market / Factor
52-Week High
$98.65$169.55
52-Week Low
$38.10$93.43
Enterprise Value
$9.34B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MP Materials

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MP Materials

MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.

Read more on MP

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI